{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T21:20:53Z","timestamp":1789852853799,"version":"4.0.1"},"reference-count":16,"publisher":"S. Karger AG","issue":"2","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Inflamm Intest Dis"],"published-print":{"date-parts":[[2017]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Background:&lt;\/i&gt;&lt;\/b&gt; The TNF-\u03b1 antagonist golimumab is approved for the treatment of ulcerative colitis but not for Crohn's disease (CD). We herein report a case series of 8 difficult-to-treat patients with severe and refractory CD receiving golimumab as an off-label rescue medication and fourth-line anti-TNF agent in our tertiary referral inflammatory bowel disease center. &lt;b&gt;&lt;i&gt;Methods:&lt;\/i&gt;&lt;\/b&gt; We performed a retrospective analysis of clinical, biochemical, and radiological as well as endoscopic parameters. The patients all suffered from severe refractory CD with ongoing symptoms. Moreover, all 8 patients had previously been treated with all 3 other TNF-\u03b1 antagonists approved for CD in Switzerland (infliximab, adalimumab, and certolizumab pegol) without durable clinical response. &lt;b&gt;&lt;i&gt;Results:&lt;\/i&gt;&lt;\/b&gt; Three out of 8 patients showed a primary nonresponse. Among the 5 patients responding after induction, 1 patient showed a loss of response, and in 1 patient, treatment was terminated due to side effects. Three patients have a continuous clinical response under golimumab. We did not observe any severe adverse events during golimumab administration. &lt;b&gt;&lt;i&gt;Conclusions:&lt;\/i&gt;&lt;\/b&gt; A considerable fraction of this highly selected subgroup of difficult-to-treat CD patients responded to golimumab, indicating a promising potential for refractory CD patients, including those with multiple previous anti-TNF exposures.<\/jats:p>","DOI":"10.1159\/000481400","type":"journal-article","created":{"date-parts":[[2017,10,18]],"date-time":"2017-10-18T21:24:02Z","timestamp":1508361842000},"page":"131-138","source":"Crossref","is-referenced-by-count":14,"title":["The Efficacy and Safety of Golimumab as Third- or Fourth-Line Anti-TNF Therapy in Patients with Refractory Crohn's Disease: A Case Series"],"prefix":"10.1159","volume":"2","author":[{"given":"Linda","family":"Russi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Scharl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Rogler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Biedermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2017,10,19]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.2.4.12304"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/art.23383"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120584"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/art.24638"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60506-7"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/art.27348"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200308"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/art.34436"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.05.048"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.06.010"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000001165"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2015.135"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2013.73"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2010.09.003"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv128"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.04130.x"}],"container-title":["Inflammatory Intestinal Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/481400","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/481400","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T17:01:24Z","timestamp":1745427684000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000481400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":16,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,11,8]]}},"URL":"https:\/\/doi.org\/10.1159\/000481400","archive":["Portico"],"relation":{},"ISSN":["2296-9403","2296-9365"],"issn-type":[{"value":"2296-9403","type":"print"},{"value":"2296-9365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}